• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Natco Pharma gets USFDA approval for lenalidomide capsules

expresspharmaMay 24, 2021

Tag: NATCO , FDA , lenalidomide capsules

Natco Pharma has received final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5 mg, 10 mg, 15 mg, and 25 mg strengths, from the US Food and Drug Administration (FDA), and tentative approval for the 2.5 mg and 20 mg strengths.

Natco Pharma gets USFDA approval for lenalidomide capsules

NATCO, along with its marketing partner Arrow International (a US affiliate of Teva Pharmaceutical Industries), previously settled the Paragraph IV litigation related to the product with Celgene (now part of Bristol-Myers Squibb), who sells the product under the brand-name REVLIMID. NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.

Previous:MSN Laboratories launches Posaconazole to treat mucormycosis

Next:COVID-19 to have long-term impact on global diabetes market: GlobalData

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Natco Pharma gets USFDA approval for lenalidomide capsules | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Nabumetone (FDA)

Nabumetone (FDA)
GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Mitomycin ( FDA)

Mitomycin ( FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Etoposide( FDA)

Etoposide( FDA)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
lribrin Benzenesulfonate (FDA GMP)

lribrin Benzenesulfonate (FDA GMP)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service